Dtsch Med Wochenschr 2021; 146(19): 1283-1286
DOI: 10.1055/a-1393-7697
Klinischer Fortschritt
Pneumologie

Therapiekonzepte des fortgeschrittenen Lungenkarzinoms im Stadium IV

Advances in Lung Cancer Treatment
Christian Schulz
  Klinik und Poliklinik für Innere Medizin II, Bereich Pneumologie, Klinikum der Universität Regensburg
› Author Affiliations
› Further Information
    Permissions and Reprints

Was ist neu?

Immunonkologische Monotherapie des nichtkleinzelligen Lungenkarzinoms 5-Jahres-Überlebensdaten der KEYNOTE-024-Studie bestätigen die anhaltende Wirksamkeit einer immunonkologischen Monotherapie bei Patienten mit nichtkleinzelligem Lungenkarzinom (NSCLC) mit hoher PD-L1-Expression (≥ 50 %).

Duale Immuntherapie in Kombination mit Chemotherapie als Erstlinientherapie des nichtkleinzelligen Lungenkarzinoms Nivolumab plus Impilimumab in Kombination mit 2 Zyklen platinhaltiger Chemotherapie verbessern das Überleben von NSCLC-Patienten.

Neue Targets und Therapieoptionen Entrectinib und Larotrectinib mit Wirksamkeit bei NTRK-Fusions-positivem NSCLC. Selpercatinib und Pralsetinib mit Wirksamkeit bei RET-Fusions-positivem NSCLC. Mobocertinib mit Wirksamkeit bei EGFRex20ins-Mutation des EGFR-Gens. Sotorasib mit Wirksamkeit bei kRAS-G12C-Mutation des NSCLC.

Nationales Netzwerk Genomische Medizin Lungenkrebs Das bundesweite Nationale Netzwerk Genomische Medizin Lungenkrebs (nNGM) ermöglicht NSCLC-Patienten den Zugang zu modernster molekularer Diagnostik und neuesten Therapieoptionen.

Abstract

Immuno-oncologic monotherapy for NSCLC 5-year survival data from the KEYNOTE-024 trial confirm the sustained efficacy of immuno-oncologic monotherapy in patients with NSCLC with high PD-L1 expression (≥ 50 %).

Dual immunotherapy in combination with chemotherapy as first-line therapy for NSCLC Nivolumab plus impilimumab in combination with 2 cycles of platinum-containing chemotherapy improves survival in NSCLC patients.

Novel targets and treatment options Entrectinib and larotrectinib with efficacy in NTRK fusion-positive NSCLC. Selpercatinib and pralsetinib with efficacy in RET fusion-positive NSCLC. Mobocertinib with efficacy in EGFRex20ins mutation of the EGFR gene. Sotorasib with efficacy in kRAS-G12C mutation of NSCLC.

National Network Genomic Medicine Lung Cancer (nNGM) The nationwide network nNGM provides NSCLC patients with access to state-of-the-art molecular diagnostics and the latest treatment options.

Schlüsselwörter

Immuntherapie - zielgerichtete Therapie - Nationales Netzwerk Genomische Medizin Lungenkrebs

Key words

immunotherapy - targeted therapy - National Network Genomic Medicine Lung Cancer


Publication History

Article published online:
22 September 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Reck M, Rodríguez-Abreu D, Robinson AG. et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016; 375: 1823-1833
    CrossrefPubMedGoogle Scholar
  • 2 Reck M, Rodríguez-Abreu D, Robinson AG. et al Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol 2021; JCO2100174. DOI: 10.1200/JCO.21.00174.
    CrossrefPubMedGoogle Scholar
  • 3 Herbst RS, Giaccone G, de Marinis F. et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med 2020; 383: 1328-1339
    CrossrefPubMedGoogle Scholar
  • 4 Paz-Ares L, Ciuleanu TE, Cobo M. et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 198-211
    CrossrefPubMedGoogle Scholar
  • 5 Doebele RC, Drilon A, Paz-Ares L. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 2020; 21: 271-282
    CrossrefPubMedGoogle Scholar
  • 6 Hong DS, DuBois SG, Kummar S. et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020; 21: 531-540
    CrossrefPubMedGoogle Scholar
  • 7 Drilon A, Oxnard GR, Tan DSW. et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2020; 383: 813-824
    CrossrefPubMedGoogle Scholar
  • 8 Riely GJ, Neal JW, Camidge DR. et al. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial. Cancer Discov 2021; DOI: 10.1158/2159-8290.CD-20-1598.
    CrossrefPubMedGoogle Scholar
  • 9 Canon J, Rex K, Saiki AY. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 2019; 575: 217-223
    CrossrefPubMedGoogle Scholar
  • 10 Li BT, Skoulidis F, Falchook G. et al CodeBreaK 100: registrational phase 2 trial of sotorasib in KRAS p.G12C mutated non-small cell lung cancer. 22nd World Conference on Lung Cancer 2020 Jan 28–31; 2021: Abstract PS01.07
    Google Scholar